Aptamers as targeted therapeutics: current potential and challenges.
about
Label-Free Aptasensors for the Detection of MycotoxinsDevelopment of Cell-SELEX Technology and Its Application in Cancer Diagnosis and TherapySelection of Nucleic Acid Aptamers Targeting Tumor Cell-Surface Protein BiomarkersMolecular simulations and Markov state modeling reveal the structural diversity and dynamics of a theophylline-binding RNA aptamer in its unbound stateBase-Modified Nucleic Acids as a Powerful Tool for Synthetic Biology and Biotechnology.Unraveling Prion Protein Interactions with Aptamers and Other PrP-Binding Nucleic Acids.Generation and Applications of a DNA Aptamer against Gremlin-1.Three-dimensional modeling of single stranded DNA hairpins for aptamer-based biosensorsNew Modalities for Challenging Targets in Drug Discovery.Hybridization chain reaction: a versatile molecular tool for biosensing, bioimaging, and biomedicine.Future strategies for the discovery of therapeutic aptamers.Current Progress in Non-viral RNAi-Based Delivery Strategies to Lymphocytes.Emerging cancer-specific therapeutic aptamers.Osteopontin at the Crossroads of Inflammation and Tumor Progression.Chemical Modifications of Nucleic Acid Aptamers for Therapeutic Purposes.Potential Diagnostic and Therapeutic Applications of Oligonucleotide Aptamers in Breast CancerIdentification of LAG3 high affinity aptamers by HT-SELEX and Conserved Motif Accumulation (CMA).Aptamers: Biomedical Interest and Applications.Recent Advances in SELEX Technology and Aptamer Applications in Biomedicine.Incorporation of aptamers in the terminal loop of shRNAs yields an effective and novel combinatorial targeting strategy.Aptamer selection and applications for breast cancer diagnostics and therapy.Nucleic Acid Aptamers: Emerging Applications in Medical Imaging, Nanotechnology, Neurosciences, and Drug Delivery.A water-soluble nucleolin aptamer-paclitaxel conjugate for tumor-specific targeting in ovarian cancer.A Novel DNA Aptamer for Dual Targeting of Polymorphonuclear Myeloid-derived Suppressor Cells and Tumor Cells.Therapeutic targeting of non-coding RNAs in cancer.Current Advances in Aptamers for Cancer Diagnosis and Therapy.Detection of human neutrophil elastase by aptamer affinity capillary electrophoresis coupled with laser-induced fluorescence using specified site fluorescently labeled aptamer.Aptamer/AuNP Biosensor for Colorimetric Profiling of Exosomal Proteins.Circular Bivalent Aptamers Enable in Vivo Stability and Recognition.Fluorescence Sensing Using DNA Aptamers in Cancer Research and Clinical Diagnostics.The application of aptamer 5TR1 in triple negative breast cancer target therapy.Development of HGF-binding aptamers with the combination of G4 promoter-derived aptamer selection and in silico maturation.Chemical modifications of nucleic acid drugs and their delivery systems for gene-based therapy.Chemistry, mechanism and clinical status of antisense oligonucleotides and duplex RNAs.RAGE-aptamer attenuates deoxycorticosterone acetate/salt-induced renal injury in mice.Favorable biodistribution, specific targeting and conditional endosomal escape of RNA nanoparticles in cancer therapy.Combined aptamer and transcriptome sequencing of single cells.AMOEBA Polarizable Atomic Multipole Force Field for Nucleic Acids.Aptamers in HIV research diagnosis and therapy.RNA Aptamers Recognizing Murine CCL17 Inhibit T Cell Chemotaxis and Reduce Contact Hypersensitivity In Vivo.
P2860
Q28066007-5DD76A50-CAD1-47A7-ABBF-1E68DE1BD633Q28080168-A0936DCB-8C71-40FB-BA7D-FA469D40C8CDQ33832781-FC67D569-2F2A-433B-BF18-14A6CA207707Q36355164-37311932-2BB7-4E44-A978-682CF627E613Q36373965-7D083DE2-E4EC-4DFA-9BE8-E085481E93DCQ38288126-D7542F23-5943-48C7-832E-E22EB6CBBC2FQ38288247-34E18630-B0F1-48EB-8C3F-D28AC161DBA8Q38288270-01BF5784-D502-4447-8E1C-AB64978676B3Q38289100-30D91D3A-3B16-4864-B19B-2FD06543DE5EQ38675885-07EC90AA-3162-44E8-B738-E86BAD68025AQ38748406-EB3CCDC0-EEFD-4929-AA64-DB8A5D5BDD97Q39230061-E24835BB-FAE4-4179-B88D-00D1B9D68CADQ39425770-B827F4E5-D97E-471B-9255-618322FFA71BQ41099667-A3270F2A-7E24-4EFB-AF7C-5F27CE3FADDCQ41573492-DE51505D-CEE2-4C3B-9A28-A8C1CAFB849FQ41661268-43D80CB4-BF35-4F13-B9FA-ABF2361DD40EQ42362135-F6204CAF-5473-45B3-92A0-B1A8145F787DQ42369507-AAC099DF-3D8D-4DD9-9610-EF2DC3464DFBQ45265302-552AE1C5-39B1-4797-91C6-BFE737F25CCCQ45873648-D439534F-D28C-4671-8751-83FA895D2C9EQ47097941-AA6DEC7D-FC46-4C0A-ADFC-88DF5E721818Q47104247-A0C475B9-20E1-47EE-B61C-171D7CCDC1B4Q47121338-F2AB2961-F536-4CFF-A845-BB41EF720C8DQ47207633-42604381-A6DB-4897-9417-2EB1A28BE1EEQ47292099-CF837586-5B96-447E-842B-9F46675E2C0BQ47561686-FCA1A0E0-9BEE-4143-8C6A-3671A35D1199Q47722606-7ABF9CDE-F4D8-4462-BCD5-BE748A27540DQ47763068-71713B5B-4361-4452-BABB-5EED2A0B6F2AQ47999311-8CC94D98-27FB-4109-82DB-CFE89F30251FQ48087924-064CABFC-64F0-4E22-AFDF-4FF660D78B85Q48187126-17D63F25-7CDD-420A-8C75-E0227EA7B34EQ48259083-5135116A-2D56-49E2-8EA7-8CC0D05F5EE6Q48282746-026EB5B9-6BD4-4951-8031-B86CEC1206A9Q48569299-CCA7F64F-4F17-40E2-8501-7EEFEB467662Q49413376-065F0F96-CBE0-4B17-A48C-1412D84A54D8Q49529515-31544E37-A14C-4ABA-992B-97B86BD71A2CQ50025458-AD495649-2D4D-4A0A-9E91-C23D325ECF32Q50041152-206FE813-14DD-4742-87E3-04F7FD89A9F5Q50066811-8520A22C-4388-48C0-9CD1-F1C0FF008511Q50149925-6BB01ACD-AF8E-4763-80A1-6E5CEDF405E9
P2860
Aptamers as targeted therapeutics: current potential and challenges.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
2016年學術文章
@zh
2016年學術文章
@zh-hant
name
Aptamers as targeted therapeutics: current potential and challenges.
@en
type
label
Aptamers as targeted therapeutics: current potential and challenges.
@en
prefLabel
Aptamers as targeted therapeutics: current potential and challenges.
@en
P2860
P356
P1476
Aptamers as targeted therapeutics: current potential and challenges.
@en
P2093
Jiehua Zhou
John Rossi
P2860
P2888
P304
P356
10.1038/NRD.2016.199
P577
2016-11-03T00:00:00Z